Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease

NCT03069014 is registered in ClinicalTrials.gov with PharmatrophiX Inc. as lead sponsor.

NCT NCT03069014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03069014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease
Lead sponsor
PharmatrophiX Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 15, 2017
Completion date
June 8, 2020
Enrollment
242 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate alzheimer's disease